Sarepta Therapeutics (SRPT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- $0.64
- Estimate
- $0.50
- Surprise
- +27.6%
- Revenue (period 2026-06-30)
- $328.7M
- Score at report (before → after)
- 5.0 → 5.1/10
Revenue source: xbrl.
How the report landed
Sarepta Therapeutics (SRPT) beat the $0.50 estimate with diluted EPS of $0.64 — a large 27.6% upside surprise. TrendMatrix's engine moved from Buy (Wait) (5.0/10) to Hold at 5.1/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates SRPT Sell at 5.3/10.
3 of the last 4 quarters beat the estimate; this quarter's +27.6% surprise compares with a -16.6% four-quarter average. Next scheduled report: 2026-11-04.
What argues against it
- Concentration risk — Product: Duchenne products
- Concentration risk — Supplier: Catalent
- Target reached (-2.0% upside)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $20.29
- Price target
- $23.15
- Stop
- $19.02
- Upside to target
- +14.1%
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
SRPT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $2.16B
- P/E (fwd)
- 8.0
- 52-week range
- $14.68–$25.32
- Off 52-week high
- 19.9%
- RSI (14)
- 57
- Volume vs avg
- 0.59×
- Score today
- 5.3/10